COVID-19 ve Hipertansiyon

TAŞKALDIRAN, IŞILAY; BAYRAKTAROĞLU, TANER

doi:10.25048/tudod.752989

COVID-19 ve Hipertansiyon

Işılay TAŞKALDIRAN, (Zonguldak Atatürk Devlet Hastanesi, Endokrinoloji ve Metabolizma Hastalıkları Bölümü, Zonguldak, Türkiye)

Taner BAYRAKTAROĞLU (Zonguldak Bülent Ecevit Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı, Zonguldak, Türkiye)

Türkiye Diyabet ve Obezite Dergisi

4 1

Yıl: 2020 Cilt: 4 Sayı: 2 Sayfa Aralığı: 155 - 159 Metin Dili: Türkçe DOI: 10.25048/tudod.752989 İndeks Tarihi: 30-09-2020

COVID-19 ve Hipertansiyon

Öz:

Çin’de, ilk kez 31 Aralık 2019’da, yeni bir ciddi akut solunum sendromu koronavirüs 2 (SARS-CoV-2)’nin neden olduğu COVID-19enfeksiyonu tespit edildi ve pandemiye sebep oldu. Hipertansiyon (HT), COVID-19 enfeksiyonunda prognozu etkileyen önemli birkomorbidite olarak karşımıza çıkmaktadır. SARS-CoV-2’nin akciğerde viral giriş reseptörü olarak anjiyotensin dönüştürücü enzim 2’yi(‘angiotensin converting enzyme-2’, ACE2) kullanması, COVID-19 enfeksiyonunda hipertansiyon tanısı olan ve ACEI/ARB tedavisialan hastalar açısından endişe yaratmıştır. Yapılan çalışmalarda HT tanısı olan COVID-19 hastalarında hastalığın daha ciddi ve dahamortal seyrettiği görülmektedir. ACEI/ARB kullanım gruplarında birçok çalışmada prognoz açısından farklılık oluşturmadığı hattabazı çalışmalarda olumlu etki oluşturduğu izlenmektedir. Ayrıca diğer antihipertansif tedavilerin de prognoz veya mortalite açısındananlamlı farklılık yaratmadığı görülmektedir. Hipertansif hastaların kan basıncı mutlaka kontrol altında tutulmalıdır. Başka bir nedenyoksa hastaların antihipertansif tedavileri değiştirilmemelidir.

Anahtar Kelime:

The COVID-19 and Hypertension

Öz:

On 31 December 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in China, caused COVID-19 infection and a pandemic. Hypertension (HT) appeared as an important comorbidity affecting prognosis in COVID-19 infection. SARSCoV- 2’s use of angiotensin converting enzyme 2 (‘angiotensin converting enzyme-2’, ACE2) as viral entry receptor in the lung has caused concern in patients diagnosed with hypertension and receiving ACEI / ARB therapy in COVID-19 infection. Studies show that the disease is more serious and more mortal in HT patients diagnosed with COVID-19. Taking ACEI / ARB, does not differ prognosis and mortality in many studies and even has positive effects in some studies. In addition, it seems that other antihypertensive treatments do not make a significant difference in terms of prognosis or mortality. Blood pressure of hypertensive patients must be kept under control. If there is no other reason, antihypertensive treatments of patients should not be changed.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727-733.
2. http://www.euro.who.int/en/health-topics/healthemergencies/ coronavirus-covid-19/ news/news/2020/3/whoannounces- covid-19-outbreak-a-pandemic. (30 March 2020)
3. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054- 1062.
5. Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: Implications for COVID-19 Cardiovasc Res. 2020;cvaa097.
6. Gutierrez F, Masia M, Mirete C, Soldan B, Rodriguez JC, Padilla S, Hernandez I, Royo G, Martin-Hidalgo A. The influence of age and gender on the populationbased incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53:166-174.
7. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med. 1994;96:313-320.
8. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, Wang J, Zhu M, Weintraub WS, Gao R. Status of hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344- 2356.
9. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145-151.
10. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574‐1581.
11. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547.
12. Hampl V, Herget J, Bíbová J, et al. Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. 2015;64(1):25-38.
13. Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405‐410.
14. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/ angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol Rev. 2018;98:505-553.
15. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.
16. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531‐538.
17. Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study. Eur Heart J. 2020;41(22):2058‐2066.
18. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMP, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.
19. Nadar S, Lip GY. Hypertension and the prothrombotic state. J Am Coll Cardiol. 2003;41:1847.
20. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757‐760.
21. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020;10.1161/CIRCRESAHA.120.317134.
22. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin- Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;e201624.
23. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052‐2059.
24. Pirola CJ, Sookoian S. Estimation of Renin-Angiotensin- Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. J Infect. 2020; S0163-4453(20) 30329-7.
25. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin- Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020;NEJMoa2006923.
26. Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol Res. 2020;158:104906.
27. Hypertension ECo. Position Statement of the ESC Council on Hypertension on ACEInhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/ Council-on- Hypertension-(CHT)/News/position-statement-of-the-esccouncilon- hypertension-on-ace-inhibitors-and-ang).

APA	TAŞKALDIRAN I, BAYRAKTAROĞLU T (2020). COVID-19 ve Hipertansiyon. , 155 - 159. 10.25048/tudod.752989
Chicago	TAŞKALDIRAN IŞILAY,BAYRAKTAROĞLU TANER COVID-19 ve Hipertansiyon. (2020): 155 - 159. 10.25048/tudod.752989
MLA	TAŞKALDIRAN IŞILAY,BAYRAKTAROĞLU TANER COVID-19 ve Hipertansiyon. , 2020, ss.155 - 159. 10.25048/tudod.752989
AMA	TAŞKALDIRAN I,BAYRAKTAROĞLU T COVID-19 ve Hipertansiyon. . 2020; 155 - 159. 10.25048/tudod.752989
Vancouver	TAŞKALDIRAN I,BAYRAKTAROĞLU T COVID-19 ve Hipertansiyon. . 2020; 155 - 159. 10.25048/tudod.752989
IEEE	TAŞKALDIRAN I,BAYRAKTAROĞLU T "COVID-19 ve Hipertansiyon." , ss.155 - 159, 2020. 10.25048/tudod.752989
ISNAD	TAŞKALDIRAN, IŞILAY - BAYRAKTAROĞLU, TANER. "COVID-19 ve Hipertansiyon". (2020), 155-159. https://doi.org/10.25048/tudod.752989

APA	TAŞKALDIRAN I, BAYRAKTAROĞLU T (2020). COVID-19 ve Hipertansiyon. Türkiye Diyabet ve Obezite Dergisi , 4(2), 155 - 159. 10.25048/tudod.752989
Chicago	TAŞKALDIRAN IŞILAY,BAYRAKTAROĞLU TANER COVID-19 ve Hipertansiyon. Türkiye Diyabet ve Obezite Dergisi 4, no.2 (2020): 155 - 159. 10.25048/tudod.752989
MLA	TAŞKALDIRAN IŞILAY,BAYRAKTAROĞLU TANER COVID-19 ve Hipertansiyon. Türkiye Diyabet ve Obezite Dergisi , vol.4, no.2, 2020, ss.155 - 159. 10.25048/tudod.752989
AMA	TAŞKALDIRAN I,BAYRAKTAROĞLU T COVID-19 ve Hipertansiyon. Türkiye Diyabet ve Obezite Dergisi . 2020; 4(2): 155 - 159. 10.25048/tudod.752989
Vancouver	TAŞKALDIRAN I,BAYRAKTAROĞLU T COVID-19 ve Hipertansiyon. Türkiye Diyabet ve Obezite Dergisi . 2020; 4(2): 155 - 159. 10.25048/tudod.752989
IEEE	TAŞKALDIRAN I,BAYRAKTAROĞLU T "COVID-19 ve Hipertansiyon." Türkiye Diyabet ve Obezite Dergisi , 4, ss.155 - 159, 2020. 10.25048/tudod.752989
ISNAD	TAŞKALDIRAN, IŞILAY - BAYRAKTAROĞLU, TANER. "COVID-19 ve Hipertansiyon". Türkiye Diyabet ve Obezite Dergisi 4/2 (2020), 155-159. https://doi.org/10.25048/tudod.752989